Apocynin attenuates pressure overload-induced cardiac hypertrophy in rats by reducing levels of reactive oxygen species.
It has been shown that angiotensin II (Ang II) is involved in cardiac remodeling mediated by NADPH oxidase-dependent reactive oxygen species (ROS). Accordingly, NADPH oxidase-dependent ROS may play a role in cardiac hypertrophy induced by pressure overload. In the present study, we sought to determine whether inhibition of NADPH oxidase prevents cardiac hypertrophy. After abdominal aorta banding to induce cardiac hypertrophy, rats were treated for 8 weeks with apocynin (Apo) or captopril (Cap). Measures of cardiac hypertrophy were evaluated. Treatment with Cap or Apo reduced the left ventricle/body weight ratio (LV/BW), LV transnuclear myocyte diameter, and atrial natriuretic factor (ANF) mRNA expression relative to those of untreated rats subjected to aorta banding. The activity of NADPH oxidase and the ROS levels were decreased in treated animals. Cap, but not Apo, decreased Ang II levels and inhibited expression of p22phox and p67phox in LVs. In conclusion, local expression of Ang II appears to contribute to pressure overload-induced cardiac hypertrophy by upregulating NADPH oxidase expression and promoting ROS synthesis. Inhibition of NADPH oxidase and elimination of ROS may prevent or repair damage due to cardiac hypertrophy.
Liu
Jinjun
J
Department of Physiology and Pathophysiology, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China.
Zhou
Juan
J
An
Wenjiao
W
Lin
Yuanxi
Y
Yang
Yubai
Y
Zang
Weijin
W
D000098:Acetophenones / Q000494:pharmacology*; D000804:Angiotensin II / Q000097:blood / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D009320:Atrial Natriuretic Factor / Q000235:genetics / Q000378:metabolism; D001483:Base Sequence; D002216:Captopril / Q000494:pharmacology; D006332:Cardiomegaly / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D017931:DNA Primers / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism*
D000098:Acetophenones; D000975:Antioxidants; D017931:DNA Primers; D004791:Enzyme Inhibitors; D010750:Phosphoproteins; D012333:RNA, Messenger; D017382:Reactive Oxygen Species; C472610:atrial natriuretic peptide, rat; C079789:neutrophil cytosol factor 67K; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D002216:Captopril; C056165:acetovanillone; D019255:NADPH Oxidases; C515768:Cyba protein, rat